×

EVIGATOR 1

What we do 1 What sets us apart 1 Our solutions 1 What we think 1
×

Global RWE 2

What we do 2 What sets us apart 2 Our solutions 2 What we think 2
×

Strategic Services 3

What we do 3 What sets us apart 3 Our solutions 3 What we think 3
0
Skip to Content
GIPAM
Why GIPAM
About
Corporate Responsibility
Careers
Services
Strategic Services
Global RWE
Evidence Synthesis
ANCHOR
ONCOCASE
EVIGATOR
Insights
News
Whitepapers & Publications
Events & Webinars
Contact
Subscribe to Newsletter
Shop
GIPAM
Why GIPAM
About
Corporate Responsibility
Careers
Services
Strategic Services
Global RWE
Evidence Synthesis
ANCHOR
ONCOCASE
EVIGATOR
Insights
News
Whitepapers & Publications
Events & Webinars
Contact
Subscribe to Newsletter
Shop
Folder: Why GIPAM
Back
About
Corporate Responsibility
Careers
Folder: Services
Back
Strategic Services
Global RWE
Evidence Synthesis
ANCHOR
ONCOCASE
EVIGATOR
Folder: Insights
Back
News
Whitepapers & Publications
Events & Webinars
Contact
Subscribe to Newsletter
Shop
Shop Feasibility assessment for indirect treatment comparisons (ITCs)
Online Shop images-1-Consulation .png Image 1 of
Online Shop images-1-Consulation .png
Online Shop images-1-Consulation .png

Feasibility assessment for indirect treatment comparisons (ITCs)

€35,000.00

Feasibility assessment for all major ITC methodologies to support HTA submissions, compliant with global market access standards.

Designed for: HTA submissions requiring robust ITCs.

Scope: Comprehensive feasibility assessment for all major ITC methodologies.

Add-on: Available as an add-on to the SLR for HTA service.

Compliance: Approach aligned with CDA, NICE, EU JCA, and other major market requirements, with tailored recommendations to local HTA preferences.

Process: Transparent flow of literature from SLR to ITCs; evaluation of network connectivity at the population and comparator levels; exploration of approaches to join networks where applicable; assessment of clinical and methodological homogeneity and other ITC assumptions; evaluation of data availability; and detailed ITC recommendations to inform a statistical analysis plan that meets HTA reporting standards.

Output: Comprehensive summary report (MS PTT or Word) with feasibility findings, recommended ITC approach, and key considerations for HTA submission.

Timeline: 4 weeks

Quantity:
Add To Cart

Feasibility assessment for all major ITC methodologies to support HTA submissions, compliant with global market access standards.

Designed for: HTA submissions requiring robust ITCs.

Scope: Comprehensive feasibility assessment for all major ITC methodologies.

Add-on: Available as an add-on to the SLR for HTA service.

Compliance: Approach aligned with CDA, NICE, EU JCA, and other major market requirements, with tailored recommendations to local HTA preferences.

Process: Transparent flow of literature from SLR to ITCs; evaluation of network connectivity at the population and comparator levels; exploration of approaches to join networks where applicable; assessment of clinical and methodological homogeneity and other ITC assumptions; evaluation of data availability; and detailed ITC recommendations to inform a statistical analysis plan that meets HTA reporting standards.

Output: Comprehensive summary report (MS PTT or Word) with feasibility findings, recommended ITC approach, and key considerations for HTA submission.

Timeline: 4 weeks

Feasibility assessment for all major ITC methodologies to support HTA submissions, compliant with global market access standards.

Designed for: HTA submissions requiring robust ITCs.

Scope: Comprehensive feasibility assessment for all major ITC methodologies.

Add-on: Available as an add-on to the SLR for HTA service.

Compliance: Approach aligned with CDA, NICE, EU JCA, and other major market requirements, with tailored recommendations to local HTA preferences.

Process: Transparent flow of literature from SLR to ITCs; evaluation of network connectivity at the population and comparator levels; exploration of approaches to join networks where applicable; assessment of clinical and methodological homogeneity and other ITC assumptions; evaluation of data availability; and detailed ITC recommendations to inform a statistical analysis plan that meets HTA reporting standards.

Output: Comprehensive summary report (MS PTT or Word) with feasibility findings, recommended ITC approach, and key considerations for HTA submission.

Timeline: 4 weeks

You Might Also Like

Automated study listing
Automated study listing
€5,700.00
Network meta-analysis (NMA)
Network meta-analysis (NMA)
€66,800.00
Early network meta-analysis (NMA) feasibility assessment
Early network meta-analysis (NMA) feasibility assessment
€25,700.00
Automated SLR protocol
Automated SLR protocol
€3,850.00
SLR on Clinical Efficacy for Health Technology Assessments
SLR on Clinical Efficacy for Health Technology Assessments
€168,252.00

Do you have questions?

CONTACT US >

Contact Us

GIPAM GmbH

Alter Holzhafen 19

23966 Wismar, Germany

Phone: +49 3841 758 1014

info@gipam-health.com

Shop Form
Please provide your contact details and we will contact you about your wishlist
Name *

Thank you for your submission.

As you’ll likely need a full contract, we’ll send you a draft within the next 48 working hours. Once received, please review the draft carefully. If you're happy to proceed, you can either sign it directly or let us know if you’d prefer to use an electronic signature process.

Should you have any feedback or request changes, we’re happy to consider them—please email Sabrina at sabrina.mueller@gipam-health.com.

Once the contract is signed, our project manager will be in touch right away to schedule your kick-off meeting.

Our Services

Strategic Services

Global RWE

Evidence Synthesis

Ask me about RWE

Learn more

News & Seminars

Whitepapers & Publications

About Us

Corporate Responsibility

Code of Conduct

Privacy Policy

Cookie Policy

Terms of Use

Connect